Monday 05 June 2023 - 00:01
NOTE: all of our usual telephone and FAX systems are currently down due to a dispute between our landlord and Verizon. We are working to remedy this situation and get our phones back on ASAP.
In the meantime, please use this mobile phone number: 978-715-9327, and this fax number: 781-491-0695.
Thank you for your patience as we work through this unfortunate outage caused by a dispute beyond our control.
Sale: 25% Off !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only - Limited Time Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
Search:
V-4703 Veliparib, Free Base, >99%
Synonyms : [A-861695] [ABT-888]

- Size
- US $
- €
- £
- ¥
- 10 mg
- 45
- 42
- 36
- 6,300
- In stock
- 25 mg
- 60
- 56
- 48
- 8,400
- In stock
- 50 mg
- 84
- 78
- 67
- 11,800
- In stock
- 100 mg
- 126
- 117
- 101
- 17,600
- In stock
- 200 mg
- 177
- 165
- 142
- 24,800
- In stock
- 250 mg
- 205
- 191
- 164
- 28,700
- In stock
- 500 mg
- 297
- 277
- 238
- 41,600
- In stock
- 1 g
- 519
- 484
- 417
- 72,700
- In stock
- 2 g
- 990
- 924
- 795
- 138,700
- In stock
- 5 g
- 1,870
- 1,746
- 1,503
- 261,900
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 32 Other Countries
- M.W. 244.29
- C13H16N4O
- [912444-00-9]
- Veliparib, also known as ABT-888, is a potent inhibitor of PARP-1 and PARP-2, with Ki values of 5.2 nM and 2.9 nM, respectively. It was demonstrated to have good oral bioavailability, to cross the blood-brain barrier well, to have modest antitumor activity alone, and to potentiate temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models. Donawho C.K., et al. "ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models." Clin. Cancer Res. 13: 2728-2737 (2007).
- This research compound is the free base form of veliparib. We also offer the dihydrochloride salt form; please see Veliparib, Dihydrochloride Salt, Cat. No. [V-4799]
- A phase 1 clinical study demonstrated that the combination of veliparib with metronomic cyclophosphamide was well tolerated and showed promising activity in a subset of patients with refractory solid tumors and lymphomas and with BRCA mutations. Kummar S., et al. "A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas." Clin. Cancer Res. 18: 1726-1734 (2012).
- Pressure-induced myogenic tone was potentiated while endothelium-dependent relaxation was reduced in diabetic mice compared with control mice. PARP-1 inhibitors INO-1001 and veliparib significantly reduced the potentiation of myogenic tone, improved endothelium-dependent relaxation, restored endothelial NO synthase phosphorylation and cGMP, and reduced cleaved PARP-1. PARP-1 inhibitors may be used to overcome diabetic microvascular dysfunction. Choi S.K., et al. "Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus." Hypertension 59: 1060-1068 (2012).
- This veliparib product is the free base form, whose CAS number is given above. The CAS number of the dihydrochloride salt form is 912445-05-7.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.